BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
BioHarvest's proprietary Olive Cell composition has reached commercial readiness, completing development, commercial-scale manufacturing validation, and the self-affirmed GRAS process. The asset is now available for licensing and commercialization through the company's CDMO business, with GMP manufacturing positioned to begin production for a future customer or partner. Preliminary in-vitro data showed Olive Cell reduced lipid accumulation by up to 37% in a liver steatosis model and collagen type I by up to 50% in a fibrosis model, though these findings have not been demonstrated in humans.
Key figures
- Steatosis lipid reduction
- up to 37%
- Fibrosis collagen reduction
- up to 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.